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Abstract: Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer.
In immunosuppressed populations it is a source of considerable morbidity and mortality due
to its enhanced recurrence and metastatic potential. In common with many malignancies,
leucocyte populations are both protective against cancer development and also play a role in
‘sculpting’ the nascent tumor, leading to loss of immunogenicity and tumor progression. UV radiation
and chronic viral carriage may represent unique risk factors for cSCC development, and the immune
system plays a key role in modulating the response to both. In this review, we discuss the lessons
learned from animal and ex vivo human studies of the role of individual leucocyte subpopulations
in the development of cutaneous SCC. We then discuss the insights into cSCC immunity gleaned
from studies in humans, particularly in populations receiving pharmacological immunosuppression
such as transplant recipients. Similar insights in other malignancies have led to exciting and novel
immune therapies, which are beginning to emerge into the cSCC clinical arena.
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1. Introduction
Cutaneous squamous cell carcinoma (cSCC) represents the second most common skin cancer in
the United States, with an increasing incidence of over 700,000 cases each year [1]. In the great majority
of cases, excision with clear margins is curative. Classical risk factors for cSCC development include
age, ultraviolet (UV) radiation exposure, ethnicity, skin phototype, and immunocompromise.
Understanding of the role of immunity in tumor development generally has evolved over
time and has been reviewed in depth elsewhere [2]. The concept that premalignant and oncogenic
virally infected cells bearing immunogenic tumor-specific antigens are detected and eliminated by
leucocytes through immune surveillance was superseded by the more complex idea of immunoediting.
Immunoediting describes the process by which elimination of tumor cells leads to positive selection
for those that have lost expression of immunogenic tumor-specific antigens, which proliferate and
develop a tumor microenvironment (TME). Immunoediting has been further refined into a three-step
process: elimination, equivalent to the original concept of ‘immune surveillance’; equilibrium, in which
immune responses control but fail to fully eliminate the sporadic malignant cells that escape destruction,
leading to ‘sculpting’ of the remaining cells; and escape, in which the selected cells are able to grow in
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an immunologically intact host, through a combination of immune evasion and immune suppression
or resistance to apoptosis.
There is no reason why this model should not apply to cSCC. However, the picture emerging
is complex: leucocyte sub-populations may play contrasting roles at different stages of cSCC
carcinogenesis. Infiltrating leucocytes of both innate and adaptive origin may play a role in tumor
antigen clearance, but certain subpopulations may be subverted and reprogrammed in vivo to
then suppress an immune response or directly promote tumor proliferation. Further complicating
matters, inflammatory mediators often act in an autocrine and paracrine fashion upon keratinocytes,
malignantly transformed cells and leucocytes, with differing effects upon each.
In this review, we discuss the current understanding of the role of individual elements of the
innate and adaptive immune system in the development of, and response to, cSCC. We then discuss
lessons learned about the role of the immune system in the clinical setting, with a particular focus on
studies in the immunosuppressed. Finally, we explore emerging data about how the immune system
itself may be harnessed to provide novel therapies against cSCC.
2. The Role of Innate Immunity
2.1. Tumor-Associated Macrophages (TAMs) and Neutrophils
Cross-talk between injured keratinocytes and resident macrophages may represent the triggering
event for circulating leucocyte recruitment leading to the development of chronic inflammation,
which plays a key role in cSCC development [3].
UVB-associated inflammation is marked by myeloid infiltration, angiogenesis, and keratinocyte
hyperproliferation in a toll-like receptor 4 (TLR4)-dependent manner in mice [4]. Proinflammatory
mediators are released by keratinocytes and infiltrating leucocytes in response to UVB irradiation or
endotoxin stimulation [3,5–7]. These mediators, particularly tumor necrosis factor α (TNFα), play a
critical role in early cSCC development in murine models [5,8,9]. Low levels of TNFα in the TME
may lead to monocyte differentiation into a macrophage phenotype that promotes local tumor growth,
angiogenesis, and immune escape [10].
In the setting of established malignancy, macrophages are one of the major tumor-infiltrating
leucocyte populations. In vitro and in animal models, primed macrophages have been demonstrated
to eradicate various (non-cSCC) tumor cell lines [11–14]. Despite this, across multiple malignancies
the presence of gene signatures associated with intratumoral myeloid populations are associated
with a poorer prognosis [15]. This paradox may be explained by TME reprogramming of myeloid
cells. Tumor-associated macrophages (TAMs) infiltrating later in cSCC carcinogenesis are likely
influenced by paracrine signaling, including TGF-β and relatively low concentrations of IFN-γ and
TNFα, promoting a humoral Type 2 T helper (Th2)-M2 (as opposed to cytotoxic Type 1 T helper
(Th1)-M1) response leading to ineffective phagocytosis and antigen presentation with acquisition of an
immunoregulatory phenotype [16–18].
Macrophages have been identified around and within excised cSCC in greater numbers than
normal skin with evidence of both M1 and M2 macrophage phenotypes [19,20]. TAMs may directly
promote tumor growth through secretion of proangiogenic factors such as vascular endothelial growth
factor (VEGF) and matrix metalloproteases (MMP). These degrade the peritumoral scaffold that might
otherwise act as a barrier to invasion [19,21].
2.2. Dendritic Cells
Dendritic cells patrol peripheral tissue and migrate to regional lymph nodes upon stimulation,
where antigen is efficiently presented particularly through Major Histocompatibility Complex (MHC)
classes I and II, initiating an adaptive response in antigen-specific T cells through cognate binding
and appropriate co-stimulatory signals. This determines the initial nature and strength of an immune
response, driving an inflammatory response that facilitates clearance of tumor, or a tolerogenic response
Int. J. Mol. Sci. 2019, 20, 2009 3 of 22
that may promote tumor growth through induction of unresponsiveness (‘anergy’) or apoptosis in T
cells [22]. Most understanding of the role of dendritic cells (DCs) in cSCC comes from murine models.
The best-described subtypes of skin-resident DCs are Langerhans cells (LCs) and monocyte-derived
dermal DCs (dDCs), though up to four other DC-progenitor-derived subtypes within the dermis
have been described [23,24]. LCs are the only DC found in the epidermis during steady state and are
long-lived and self-renewing [25].
UV radiation induces a functional and quantitative reduction in systemic immune responses.
UV radiation induces both DC apoptosis and lymph node migration, leading to depletion in the
skin [26–29]. However, both lymph node migration and antigen presentation are impaired by UV
radiation leading to a reduction in DC-mediated inflammation and promotion of Th2 and regulatory
T cell responses [29–33]. dDCs may be differentially activated compared to LCs, more efficiently
promoting cytotoxic responses partly through cross-presentation to CD8+ T cells [34].
Large-scale, genome-wide, and transcriptome-wide association studies have identified certain
MHC Class II (HLA-DR and -DQ) single nucleotide polymorphisms (SNPs) that may be associated
with increased cSCC risk in humans [35]. The effects of these have not been elucidated mechanistically
but could relate to altered antigen presentation by DC to effector cells.
Whilst reduced numbers of LCs have been described in excised cSCC and Bowen disease (SCC in
situ) compared to normal skin, it is difficult to interpret the significance of this, given that many of the
effector functions of these cells lie elsewhere and may indicate enhanced migration to draining lymph
nodes [20,36].
Constitutive absence of LC in chemically-induced cSCC appears to inhibit inflammation and
mutagenesis required for tumor initiation and progression [37,38]. Conditional depletion of LCs and
dDCs has conversely suggested an anticarcinogenic role though TNFα-mediated natural killer (NK)
cell recruitment and activation [39,40]. DCs dampen inflammation initially in UVB-damaged murine
skin through phagocytosis of apoptotic keratinocytes [41], but they subsequently promote tumor
progression in an IL-22- and TGFβ1-dependent manner [31,42]. Despite mouse data to suggest the
opposite, human LCs from established cSCC induce a strong T helper 1 (Th1) response in vitro even in
the presence of tumor supernatant, whilst dermal DCs and monocyte-derived DCs show impaired
function in the same setting [43,44].
Taken together, environmentally-induced altered DC function could facilitate early immune
evasion and promote tumor development. LC dysfunction may not be sustained once the TME is
established, unlike dDC dysfunction, which may be more important in the failure to mount adequate
cytotoxic responses.
2.3. Myeloid-Derived Suppressor Cells (MDSCs)
The tumor milieu is able to pathologically induce immature myeloid precursor differentiation
into a heterogeneous population of both monocytic and granulocytic lineages that demonstrate
immunosuppressive properties and leads to reduced immunosurveillance and immune responses,
termed myeloid-derived suppressor cells (MDSCs) [45]. MDSC accumulation within multiple
malignancies has been associated with a poorer prognosis [46].
Little is known about the role of MDSC in cSCC. The generation and suppressive activity of MDSC
in chemically-induced cSCC may be IL-6 dependent [47]. Various strains of human papillomavirus
(HPV), which may be implicated in cutaneous cSCC development, have been shown to induce
MDSC [48]. Based on other malignancies it is presumed that MDSCs inhibit antitumor responses and
promote cSCC development.
2.4. Natural Killer (NK) and Innate Lymphoid Cells
Innate lymphoid cells (ILCs) belong to the lymphoid lineage but lack T- or B- cell receptors and
do not express myeloid or dendritic cell markers. They are subdivided with ILC1 associated with Th1
responses, ILC2 with Th2, and ILC3 with Th17 responses [49].
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NK cells are the best understood ‘cytolytic’ ILC1 population. Multiple localized subsets can be
identified using cell surface markers, which recognize and kill tumor cells through killer receptors [50,51].
Patrolling NK cells are found in the human and murine dermis but rarely in the epidermis [52].
NK cells play a critical role in suppressing cSCC development in murine models [39], though the
TME may modulate their cytotoxicity through downregulation of activating receptors [53]. Genetic or
acquired impaired function or reduced number of NK cells is associated with increased risk of
herpesvirus, papillomavirus, and cSCC in humans [54–57]. This indicates that NK cells play a key role
in immunosurveillance against cSCC development.
Some NK cell populations may demonstrate features of immunological memory,
including persistently enhanced function following activation. This appears to be particularly
important in response to chronic, latent viral infection, and in vivo these populations may show
enhanced antitumor activity [58,59]. It is possible, though unexplored, that chronic viral infections
such as HPV may induce alterations in this process.
Other noncytotoxic ‘helper’ ILC1, ILC2, and ILC3 populations have been described, but their
role in cancer is more controversial [60]. ILC2 and ILC3 populations may promote tumor growth and
spread through cytokine effects (particularly through IL-33 and IL-22), but they may also promote the
formation of tertiary lymphoid structures that promote cytolytic adaptive responses [49,61]. In health,
ILCs are preferentially found in ‘barrier’ tissues such as the skin (in contrast to NK cells, which are
predominantly blood-borne) and have been demonstrated to play a role in cutaneous inflammation.
Their role in cSCC carcinogenesis has yet to be explored [62].
2.5. Atypical T Cells
Two populations of T cells (γδ T cells and natural killer T cells) that display attributes of both
innate and adaptive immunity are described. They express somatically rearranged receptors but may
lack potential for establishing antigen-specific clonal memory populations. Both are able to secrete
effector cytokines and engage in cell-mediated killing, akin to NK and CD8+ T cells.
Gamma-delta (γδ) T cells are a population of predominantly CD3+CD4−CD8− and
CD3+CD4−CD8+ T cells bearing an atypical T cell receptor (TCR) containing a gamma and a delta
chain that recognizes cells that present unprocessed, nonpeptide phosphorylated compounds [63].
These compounds are generated naturally under conditions of stress and are also found within
microbial structures. In a recent analysis of the gene expression profile of thousands of samples
from thirty-nine distinct human cancers, intratumoral γδ cell signatures correlated with a favorable
prognoses [15]. Subsets of human γδ T cells have been defined based on use of one of two variable
regions of TCR-δ [64]. Mice have different subsets of γδ T cells, of which the dendritic epidermal γδ T
cells (DETCs) are the best studied [64].
DETCs patrol the skin, though they are still significantly outnumbered by their αβ T cell
counterparts [40]. γδ cell knockout has demonstrated their role in protection against chemical-induced
cSCC carcinogenesis in both a killer cell receptor- (NKG2D) and IgE-dependent manner [40,65].
More recent work suggests a potential tumor-promoting role for γδ cells in a murine model of
HPV-induced epithelial malignancy, where IL-17A-producingγδ subsets were associated with increased
angiogenesis [66]. γδ cells appear to represent only a minor subset of tumor-infiltrating lymphocytes,
and their role within human cSCC is unknown.
Natural killer T (NKT) cells represent 2%–3% of splenic T cells in mice and express intermediate
levels of the classical αβ TCR. They express a restricted TCR repertoire and recognize glycolipid
and nonlipid antigens, which are expressed on the nonclassical MHC Class I-like antigen-presenting
molecule CD1. These cells efficiently suppress and activate both innate and adaptive immune
responses [67].
NKT cells have been indirectly associated with a pro-carcinogenic role in UVB-induced cSCC.
CD1d knockout leads to reduced UVB-induced inflammation, carcinogenesis, and a lack of functional
NKT cells [68,69]. Adoptive transfer of splenic T cells from chronically irradiated mice leads to a
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failure to reject transplanted cutaneous malignancy—an effect lost when NKT cells were depleted [70].
Like γδ cells, their role in cSCC development in humans remains unclear.
3. The Role of Adaptive Immunity
3.1. Cellular Immunity
T cells play a major role in the immune response to tumor antigens. Up to 10% of tumor-infiltrating
cells are T cells, both within the tumor and at tumor margins [71].
Activation of T cells is driven and directed by antigen presenting cells, leading to polarization of
T cell responses. Multiple ‘axes’ of CD4+ T cell activation and differentiation have been described,
including Th1, Th2, Th9, and Th17 (summarized in Table 1). A recent review excellently described the
contrasting roles different Th subclasses generally play in the development of malignancy [71].
Table 1. Summary of described T cell polarization axes and their role in cutaneous squamous
cell carcinoma (cSCC). In italics is a summary of the role of each axis in cSCC development. IL,
interleukin; IFN, interferon; TGF, transforming growth factor; TNF, tumor necrosis factor; and CCL,
chemokine ligand.
Axis Cytokines DrivingDifferentiation
Hallmark Effector
Cytokines Postulated Evolutionary Role and Role in cSCC Reference
Th1 IL-12, IL-18, IFN-γ,IL-2, IL-28 IL-2, IFN-γ, TNF-α
Intracellular pathogen elimination with activation
of microbicidal activity of macrophages. Typically
associated with activation of CD8+ T cells.
Generally associated with an antitumor role in cSCC.
[71]
Th2 IL-2, IL-4, IL-33 IL-4, IL-5, IL-6,IL-13, IL-25
Extracellular pathogen and parasitic elimination.
Typically, with activation of B cells and humoral
responses.
Generally associated with cSCC development.
Th9 IL-4, TGF-β IL-9, IL-10
Extracellular pathogen and parasitic elimination
(associates with Th2 responses and may represent
a subtype). Associated with allergic inflammation
and inflammation in skin.
May play antitumor role in the skin, from mouse models
of melanoma (role in cSCC specifically unknown).
[72]
Th17 IL-1, IL-6, IL-21,IL-23, TGF-β
IL-17, IL-21, IL-22,
CCL20, TNF-α
Extracellular pathogen and fungal elimination by
enhancing neutrophil responses.
Variably found to be pro- and anti-neoplastic in different
models and settings (role in cSCC specifically
unknown).
[73]
Th22 IL-23, IL-6 IL-22, TNF-α
May drive epithelial innate immune responses.
Tissue repair post-injury—induces keratinocyte
proliferation.
May drive tumor proliferation in cSCC.
[74]
Tfh IL-6, IL-21, TGF-α IL-17, IL-21
Regulation of antigen-specific B cell responses and
antibody production through germinal center B-T
cell interaction.
Role in cSCC unknown (though presumed to act
indirectly through B cell functions).
[75]
Treg TGF-β, IL-2 IL-10, TGF-β
Regulatory: induction of tolerance and T cell
anergy. Suppression of effector responses.
Suppresses tumor immune responses in cSCC.
[71]
Specifically regarding cSCC, tumor-specific T cell responses are critical for prevention of cutaneous
malignancy development and metastasis; these are generally cytotoxic responses mediated via Th1
pathways [76,77]. Irradiation and chemical cSCC models induce Th17 responses, which promote cSCC
development in murine knockout models [78–80]. UVB irradiation inhibits effector CD4+ and CD8+ T
cell responses against DNA damage in murine models [74].
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IL-22 is a hallmark of Th22 responses, and it is also seen in benign skin conditions characterized by
increased keratinocyte turnover. This cytokine is upregulated in cSCC and drives tumor proliferation
in vitro [81]. T cell ‘crawl out’ analysis from explanted cSCC from organ transplant recipients (OTRs)
found increased Th22 expression compared to cSCC from nonimmunosuppressed individuals [81].
T follicular helper (Tfh) cells provide support within germinal centers for the development and
maturation of antigen-specific B cell responses and antibody production [75]. Emerging data suggests
that Tfh-dendritic cell interactions may play a critical role in generating a germinal center reaction to
intradermal antigens [82]. Whilst these cells are presumed to be integral to the development of B cell
responses in cSCC (see ‘humoral immunity’, below) their role specifically has not been explored.
Counterbalancing ‘effector’ T cell responses are ‘regulatory’ T cell (Treg) populations.
Whilst multiple regulatory T cell populations have been identified, the canonical Treg population in
humans possesses the phenotype CD4+CD25hiCD127loFOXP3+ [83–86].
Treg are found within the tumor bed of most malignancies, including cSCC, and their frequency
is often correlated with a poorer prognosis [87–90]. Upon activation, Treg inhibit effector responses
through a number of direct and indirect mechanisms. They act upon effector cells, preventing cytokine
secretion and proliferation, and antigen presenting cells, where they reduce the quality of antigen
presentation or alter the balance of costimulatory signaling towards inhibition of effector activation.
This is summarized in the setting of malignancy in Figure 1.
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Figure 1. Mechanisms contributing to regulation of tumor clearance by effector cells. APC,
antigen presenting cell. In this context, an APC may be a macrophage, dendritic cell (or Langerhans
cell) or B cell. Regulatory cells may represent various populations, including Treg, B cell regulatory
populations, and myeloid-derived suppressor cells (MDSCs). Effector cell relates predominantly
to CD8+ T cells, but may also include natural killer (NK), natural killer T (NKT), gamma-delta
T, and cytotoxic CD4+ T cells. The above mechanisms contribute to effector, particularly CD8+,
cell dysfunction and lead to a failure of tumor clearance. Those mechanisms highlighted in blue
represent mechanisms of immune escape for the tumor. Examples of relevant mediators for each
pathway are provided in brackets. Solid arrows represent mechanisms directed against specific cells
through cell contact, whilst dashed arrows represent nonspecific mechanisms through remodeling of
the tumor microenvironment (TME).
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UV irradiation leads to cutaneous infiltration of Treg and induction of Treg from infiltrating T cells.
Later in cSCC carcinogenesis, TGF-β is produced by malignant cells, which can induce infiltrating
effector T cell conversion to Treg in other malignancies [91,92]. Treg are found in greater numbers in
cSCC compared to normal skin, and they are more frequent in moderately and poorly differentiated
cSCC compared to well-differentiated lesions [91]. Knockout of IL-10 in murine models prevents
UV-induced carcinogenesis by impairing Treg function [76].
3.2. CD8+ T Cells
CD8+ T cells are essential for elimination of tumors in animal models [93–95], classically in parallel
with Th1 responses, suggesting a key role in immunosurveillance. CD8+ T cell knockout leads to
increased cSCC burden in chemical and irradiation models [78,80]. Surprisingly, a transgenic model
using an HPV oncogene failed to find a protective role for CD8+ T cells against cSCC development [96].
Within the established TME, infiltrating CD8+ T cells often fail to clear tumors due to a number of
mechanisms that lead to anergy and exhaustion (Figure 1). Within metastatic cSCC, inhibitory receptors
(and potential markers for exhaustion) including Tim-3, cytotoxic T-lymphocyte–associated antigen
4 (CTLA-4), and programmed death-1 (PD-1) are frequently found on CD8+ T cells [97]—the
presence of their ligands within cSCC, specifically PD-L1, is associated with poorer outcomes [98].
Local signaling may induce CD8+ T cells to develop a pathogenic role within cSCC, promoting tumor
proliferation [81,99]. Infiltrating CD8+ T cells can be induced to demonstrate regulatory functions
within other malignancies [100,101].
3.3. Humoral Immunity
B cells undertake effector functions through immunoglobulin (antibody) production as well as
antigen presentation and production of effector cytokines, which contributes to polarization of T
cell responses [102–104]. It was, therefore, long-held that B cells played an antitumor effector role.
However, populations of B cells with regulatory properties ex vivo have been described in both animals
and humans recently [105–109]. Thus, B cells, in common with other leucocyte populations, may play
a role both in cancer progression and cancer immunity [110].
In animal models of chemically and genetically driven cSCC, knockout of B cells leads to a
failure of carcinogenesis. This may be due to the proinflammatory and chemotactic role played by
B cell-produced immunoglobulin, with stromal immune complex deposition early in carcinogenesis
leading to myeloid activation via Fc receptors [111,112]. B cells may also directly suppress the immune
response to cSCC in a TNFα- and IL-10-dependent manner [113]. B cell-derived IgE, produced in
response to chemical carcinogenesis, may protect against cSCC development by promotingγδ responses
in mice [114]. This suggests that the role of B cells may depend on the specific mutagen used to trigger
carcinogenesis and the resultant dominant antibody class response.
In humans, an increased proportion, but not absolute number, of memory cells within the B cell
compartment is independently associated with an increased risk of subsequent cSCC in OTRs [115].
Within established tumors, there is a reduced density of CD20+ B cells in OTRs compared to cSCC from
the general population. How either of these findings translate mechanistically is unclear, particularly as
many B cell immune functions are mediated at a distance from the tumor, such as in regional lymph
nodes and in the bone marrow.
4. Lessons Learned from The Clinical Setting
4.1. Lessons Learned from Immunosuppressed Individuals
Systemic immunosuppression arising iatrogenically or through systemic disease is a significant
risk factor for cSCC development. In the context of immunosuppression, cSCC are frequently multiple
and tend to be more aggressive with a much higher burden of disease [116–122]. This provides
compelling evidence for a role of the immune system in cSCC, and studying immunosuppressed
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populations has provided important insights into how the immune system contributes to cSCC
development and progression. These immune mechanisms are complex, involving the interplay
of reduced immunosurveillance/immunoediting, immunosenescence, the dynamic anti-tumor and
pro-tumor influences of specific immune cells within the TME, and possibly a role for oncogenic viruses.
With an overall risk for cSCC up to 200-fold greater than age-matched, immunocompetent
populations, OTRs are the best studied of the immunosuppressed populations with regards to
cSCC [116]. cSCC is the most common post-transplant malignancy, and it exhibits a more aggressive
disease course with a metastatic risk double that of the general population [123]. Median survival after
metastasis is only two years [117–121,123].
cSCC burden in OTRs strongly correlates with increasing time after transplantation and intensity
of immunosuppression, providing evidence for a dose-dependent effect on cSCC pathogenesis and
prognosis [122,124,125]. Correlating with the intensity of immunosuppression needed to prevent
allograft rejection, the highest risk is seen in cardiac and lung transplant recipients, then pancreas
and/or kidney recipients, then recipients of liver transplants [125]. Increasing age at transplantation is
also a strong predictor for the development of further cSCC and may correlate with increased duration
of immunosuppression but also age-related changes in immunity (see below) [126,127]. Reducing the
intensity of immunosuppression may reduce the risk of cSCC development, providing the rationale for
modest dose reduction in patients who develop numerous cSCCs [124,128].
Populations immunosuppressed due to systemic disease also exhibit moderately increased cSCC
risk, providing more evidence that it is immunosuppression driving this phenomenon, rather than
other potential confounders such as host cancer risk factors and lifestyle factors. This includes
chronic lymphocytic leukemia (8× increased risk) and non-Hodgkin lymphoma (5× increased
risk) [117,129–132]. Patients with HIV infection have a 2.6-fold increase in cSCC risk, which correlates
inversely with CD4 count [129,133]. Patients with rheumatoid arthritis immunosuppressed with
methotrexate for disease control have a two- to four-fold increased risk of cSCC development compared
to the general population [134], and exposure to thiopurines in patients with inflammatory bowel
disease is associated in most studies with a significantly increased cSCC risk of up to five-fold [135].
The significantly elevated cSCC risk in OTRs specifically may be explained by the greater intensity
of continuous immunosuppression with multiple agents, as well as the direct tumorigenic effects of
certain agents (discussed below) [136].
4.2. The Effects of Immunosuppression on Immune Phenotype and Cutaneous Squamous Cell Carcinoma
(cSCC) Risk
As discussed earlier, the role of immunity in cSCC development centers on the concepts of
immunosurveillance and immunoediting. In the context of immunosuppression, dysfunction and
suppression of specific leucocyte subsets peripherally and at the level of the TME impacts on these
overall immune functions, resulting in the observed increased cSCC risk.
Alterations in various circulating leucocyte populations have been indirectly linked to the
increased aggressiveness of cSCC in immunosuppressed individuals [55,115,137–139]. This work
has particularly focused on OTRs. Early studies suggested that a low peripheral blood CD4+ count
predicted OTRs at increased risk of cSCC; however, the patients included were within their first
10 years post-transplantation where cSCC incidence is relatively low and has not been consistently
replicated [55,140,141]. More recent studies identified that greater numbers of peripheral blood
CD4+CD25hiCD127loFOXP3+ Tregs are found in OTRs with a history of cSCC, and may also predict
OTRs at increased risk of cSCC recurrence [55,115]. However, this predictive value may be relatively
short-term and only for high-risk cSCCs [55,115]. The proportion of circulating T cells with a fully
demethylated ‘Treg specific demethylated region’ within the FOXP3 promoter (TSDR, proposed as a
more specific marker of ‘true’ Treg) was greater in OTRs with a history of cSCC [137]. Functional studies
have demonstrated that preservation of a peripheral blood Th1 effector response against tumor antigens
(quantified by IFN-γ production) may be associated with reduced susceptibility to cSCC in OTRs [138].
Int. J. Mol. Sci. 2019, 20, 2009 9 of 22
OTRs with previous cSCC have also been observed to have lower overall numbers of B cells,
with class-switching from naïve to memory phenotype observed [115]. Low numbers of NK cells are
also associated with an increased cSCC risk in OTRs, although these observations are likely to be most
relevant in patients on azathioprine, which is known to reduce numbers of both NK and B cells [139].
CD57 has been identified as an accurate marker of T cell senescence, expressed on terminally
differentiated effector T cells that may display impaired proliferation and reduced effector cytokine
production [139]. Stratification by CD57 expression on circulating CD8+ T cells identified OTRs at almost
three-fold increased risk of developing subsequent cSCC after correction for potential confounders,
a marker superior to most clinical indicators [139]. It is postulated that excess immunosuppression
may promote T cell senescence through recurrent episodes of subclinical latent viral reactivation
(e.g., cytomegalovirus, human papillomavirus, and Epstein–Barr virus) and subsequent inflammation,
which over time leads to repeated rounds of antigenic stimulation and the accumulation of oligoclonally
expanded senescent T cells. However, this has not been demonstrated directly [139]. Additionally,
accumulation of CD57+ cells also correlates with loss of CD4+ and CD8+ central memory T cells,
another important source of antitumor immunity [94]. Overall, immunosuppression may result
in a reduced T cell antigen repertoire and impaired immunosurveillance, which promotes cSCC
development and progression through immune evasion, one of the key hallmarks of cancer [142].
4.3. The Effects of Immunosuppression on the Tumor Microenvironment
Interactions between malignant and nonmalignant host cells constitute the TME, which is driven by
complex, dynamic intercellular communications via networks of chemokines, cytokines, growth factors,
and inflammatory and matrix remodeling enzymes [143]. Several nonmalignant cell types are found in
the TME, including leucocytes, cells of the vasculature and lymphatics, fibroblasts and other cells of
the stroma. The roles of these cells, their regulation, and their effects on tumor progression have been
reviewed extensively elsewhere [143–145]. Cellular and molecular phenotyping of the TME in various
cancers, in particular the immune infiltrate, have provided important insights into antitumor immune
responses and tumor escape. This has improved our understanding of the role of the immune system
in carcinogenesis, particularly in the context of immunosuppression [144]. Immunophenotyping has
led to the identification of specific subclasses of immune TME that have varying effects on tumor
initiation and can be used as biomarkers to predict response to immunotherapy [146].
In established cSCC, quantifying infiltrating leucocytes has consistently demonstrated a
reduced density of intra- and peritumoral immune cell infiltrates in the context of chronic
immunosuppression compared to nonimmunosuppressed controls, specifically CD4+ and cytotoxic
CD8+ T cells [55,119,147,148]. In contrast, and reflecting what is observed peripherally, Treg numbers
appear to be increased in the TME in immunosuppression [55,81,138]. The frequency of FOXP3+ Tregs
in cSCC correlates with primary tumors that metastasize and overall poorer clinical outcomes [149].
Antigen presentation capacity in the TME is reduced in immunosuppression-related cSCC with
reduced numbers of CD123+ plasmacytoid dendritic cells (pDCs) observed across the spectrum
of cSCC neoplastic progression, with consequent reduction in signaling of IFN-γ, the prototypical
Th1 cytokine [148]. In immunocompetent humans there is a mix of Th1- and Th2-associated gene
expressions within established cSCC. However, within the cSCC of immunosuppressed individuals
there is a skew away from Th1 towards Th2-associated gene expression and cell infiltration. There is
also evidence of a reduction in expression of some but not all Th17-associated genes, though there
does not appear to be a reduction in intratumoral Th17 cells, compared to non-immunosuppressed
controls [81,150]. There is now mounting evidence that a predominantly T helper 2 (Th2) polarized
microenvironment results in cSCC progression, and this is the microenvironment that appears to
develop in the context of chronic pharmacological immunosuppression [78,150].
Our understanding of how immunosuppression affects the leucocytes in the TME is complicated by
the heterogeneity in treatment regimens used in OTRs. Moreover, data on the pro- and anti-carcinogenic
effects of the different immunosuppressant drugs is often conflicting and difficult to discern from
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epidemiological studies [116]. Each has different mechanisms of action and are given in combination to
minimize the risk of allograft rejection [151]. Some agents have direct mutagenic effects that contribute to
increased cancer risk. For example, azathioprine causes UVA photosensitivity, increased UVB-induced
mutagenesis and recent genomic analysis has identified a novel azathioprine-associated mutational
signature in cSCC that reveals a likely interplay with transcription-coupled nucleotide excision
repair [152,153]. The main classes of immunosuppressant medications used in OTRs, their mechanisms
of action, and effects on the immune system and tumor biology are summarized in Table 2 below.
Table 2. Summary of the main classes of immunosuppressant drugs, their main effects on the immune
system and additional mechanisms at play in cSCC pathogenesis. 6-MP, 6-mercaptopurine; Aza,
azathioprine; IL, interleukin; IMDPH, inosine monophosphate dehydrogenase; mTOR, mammalian
target of rapamycin; MMF, mycophenolate mofetil; TGF-β, transforming growth factor-β; UV, ultraviolet;
and VEGF, vascular endothelial growth factor.
Class (Drugs) Effects on Immune System Additional Mechanisms in cSCC
Calcineurin
inhibitors
(ciclosporin,
tacrolimus)
Bind to intracellular proteins, called immunophilins,
to block the effect of calcineurin, which results in
reduced production of IL-2 and reduced proliferation
of T cells [154]. IL-2 is needed for T cell activation
and expansion [155]. Indirectly inhibit monocyte
function by suppressing production of γ-IFN,
macrophage inhibitory factor, and macrophage
chemotactic factor [155]. As a result, IL-l production
by monocytes is inhibited. IL-l is a cofactor for
activation of T-helper lymphocytes.
Inhibit DNA repair mechanisms,
acting synergistically with UV in DNA
damage [116,156]. Stimulate tumor
growth via VEGF-mediated
angiogenesis [157]. Increased
invasiveness of cells via TGF-β
production [158].
Purine analogues
(azathioprine,
mycophenolate
mofetil)
Aza: prodrug which is converted to 6-MP and
metabolized to cytotoxic thioguanine nucleotides,
which are responsible for immunosuppression,
inhibiting DNA synthesis and inducing apoptosis.
Inhibits proliferation of all leucocytes [159,160].
MMF: prodrug of mycophenolic acid, which inhibits
purine synthesis by inhibiting IMDPH.
Preferentially suppresses T and B lymphocytes [161].
Aza: direct mutagenic effects on DNA
and acts synergistically as a
chromophore with UV-A to increase
sensitivity of cells to DNA damage
[152,153].
mTOR inhibitors
(sirolimus,
everolimus)
Block signaling of the mTOR serine/threonine protein
kinase, which suppresses cytokine-driven
T-lymphocyte proliferation and activation [154]. Also
impairs dendritic cells (DCs), B cells, NK cells,
neutrophils [162].
Reduce risk of cSCC: Inhibit
angiogenesis by suppressing VEGF
[157]. Promote memory T cell function
and promote autophagy-mediated
DNA repair [116].
4.4. A Role for Viruses in Cooperation with the Immune System?
An infectious contributor to cSCC development has long been hypothesized given its similar
increased incidence compared to other immunosuppression-associated cancers caused by oncogenic
viruses such as Epstein–Barr virus (EBV, post-transplant lymphoproliferative disorder) and human
herpes virus 8 (HHV-8, Kaposi sarcoma) [116]. Indeed, genetic defects that result in susceptibility to
persistent cutaneous infection by human β-papilloma viruses are associated with greatly increased risk
of cSCC development [163]. Mechanistic studies in keratinocytes have demonstrated the ability of viral
oncogenes to cause failure of DNA repair and apoptosis in cooperation with UV radiation, cell-cycle
dysregulation and transformation whilst epidemiological studies have consistently demonstrated
an association between β-PV and keratinocyte cancer, particularly in immunosuppression [164–166].
However, transcriptome analysis has failed to demonstrate that the HPV is actively replicating within
cSCC. To date, there is insufficient evidence to confirm an unequivocal causal role, and this remains an
area of controversy [167]. Overall, HPV burden may be more critical than specific HPV type [168],
and impaired viral effector responses may indirectly play a role in carcinogenesis.
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4.5. Therapeutic Modulation of the Immune Response
Uncoupling the mechanisms of T cell co-stimulation has provided important insights into
how tumors evade the immune system at the level of the TME, heralding a revolution in
immunotherapy that has transformed cancer care and outcomes for advanced and metastatic
disease [169]. Studying the TME across many cancers has identified upregulation of immune checkpoint
co-signaling proteins such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed
death-1 (PD-1), which effectively act as brakes on antitumor immune responses [169,170]. Ipilimumab,
an anti-CTLA-4 monoclonal antibody, was the first-in-class checkpoint inhibitor that demonstrated a
clear survival advantage in metastatic melanoma and was FDA-approved in 2011 [171]. Since then,
antibodies inhibiting the PD-1/PD-L1 immune checkpoint, such as nivolumab and pembrolizumab,
have demonstrated a more favorable safety profile and improved efficacy [172].
Tumors with a high mutation burden respond best to checkpoint inhibitor immunotherapy,
which is in part thought to be due to their increased neoantigen load and corresponding
immunogenicity [173,174]. As a primarily UV radiation-driven tumor, cSCC is one of the most
highly mutated cancers with a mutational load of around 50 mutations per megabase of DNA, which is
higher than melanoma and second only to basal cell carcinoma [175]. There have been anecdotal
case reports of anti PD-1 treatment in advanced cSCC, and a recent phase 2 study of cemiplimab (an
anti-PD-1 monoclonal antibody) in patients with locally advanced and metastatic cSCC demonstrated
a response rate of 47% and durable disease control in 61% [176]. Clinical trials with other anti-PD-1
agents such as pembrolizumab are in progress (clinicaltrials.gov)
In a recent study using immunohistochemistry to profile PD-1/PD-L1 expression in the cSCC
TME, PD-1 expression was found on 80% of CD8+ T cells, 73% of CD4+ T cells, and PD-L1 expression
was found on 26% of tumor cells [177]. Immunosuppression did not appear to alter this phenomenon.
Overexpression of PD-L1 in cSCC in the absence of a significant CD8+ T cell infiltrate was associated
with increased metastatic risk and was also identified in lymphatic metastatic disease providing further
evidence for the positive prognostic role of peritumoral CD8+ T cells [178]. In OTRs, the CTLA-4 and
PD-1 axes have an important role in influencing the balance between Treg induction and effector T cell
function to restrain or promote allograft responses [170]. There have been published case reports of
OTRs suffering acute graft rejection and subsequent graft failure following treatment with anti-PD-1
therapy, including one patient with advanced cSCC [179–181]. Consequently, organ transplantation is
a relative contraindication for checkpoint inhibitor therapy, and ORTs are excluded from clinical trials
at present. Ultimately, the transplant patient with advanced cSCC may be left with the unpalatable
choice of a shorter life expectancy with a functioning transplant or a longer life expectancy but with
the potential of losing their organ transplant.
Adoptive cell transfer using chimeric antigen receptor T cells (CAR-T cells) is a novel,
highly personalized immunotherapy that has shown impressive efficacy in hematological cancers,
and it is currently licensed for certain childhood leukemias [182]. Extracted and expanded T cell
populations are bio-engineered to exhibit specificity for tumor surface antigens before re-infusion back
into the patient for tumor elimination [183]. CAR-T therapy for solid tumors is currently undergoing
clinical trials and may represent a potential future treatment option for cSCC with less risk of triggering
‘off target’ immune responses to a transplant [182].
5. Conclusions
The immune system plays a key role in cSCC pathogenesis and progression that is multifaceted
and complex. Transgenic animal models have provided important insights into the roles of specific
leucocytes in keratinocyte cancer biology, but they are limited by differences in murine-human immune
and tumor phenotypes and simplistic cancer induction models. Studying cSCC in immunocompetent
and immunosuppressed individuals has uncoupled many of the immune mechanisms at play in
cSCC pathogenesis and progression. In humans there is unlikely to be a single ‘trigger’ for cSCC
development per se, with a combination of genetic and environmental (including viral, chemical,
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and radiation) factors culminating in malignant transformation in keratinocytes. It is not clear how
current models can ‘tease out’ which are the dominant effects, and thereby the most likely role of
individual leucocyte lineages, in cSCC.
The clinical visibility of cutaneous premalignant lesions not only permits early diagnosis and
excision where required but also provides an opportunity to understand the early events that
precede the development of overt cSCC. In this regard, interrogation of both premalignant and
malignant tissue in greater depth may facilitate greater understanding of the proteomic, genomic,
and immunological landscape.
Intensive study of the TME across cancers including cSCC has begun uncoupling the complex,
dynamic interactions at play between tumors and the multitude of host innate and adaptive immune
cells and the mechanisms of immune evasion that evolving cancers employ. This improved knowledge
is driving forward a revolution in immunotherapies that has changed the landscape for metastatic cancer
therapy, providing novel treatment options for advanced and metastatic cSCC. However, our current
understanding of the role of immunity in cSCC is far from complete, with conflicting data from many
animal and human studies. Part of the problem arises from limitations in our ability to accurately profile
leucocytes at high resolution, with their different activation states, spatial orientations, and multitudes
of receptors, compounded by significant tumor and immune heterogeneity. Novel techniques are
now becoming mainstream such as mass imaging cytometry and multiplex gene expression analysis,
which promise accurate, high-throughput, and deep immune phenotyping with spatial resolution that
will hopefully overcome these limitations and herald a new era in cancer immunology. As always
with such technologies that produce high dimensional data, interpreting and interrogating the output
will likely be the rate-limiting step. The need for computational tools and algorithms to decipher the
complex interactions of the TME to bring about translational benefit to patients will be essential.
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